Crystal Genomics will supply $2 million of Acelex, an osteoarthritis drug, to Russia. According to the company on the 7th, this order is based on a supply contract with PharmArtis International, a Russian state-run pharmaceutical company. This is the second order quantity. The contractual obligation to purchase is $43.86 million. Crystal Genomics will receive up to $77.6 million in milestones based on additional sales. PharmArtis is currently developing sales and marketing strategies and more. It will officially release Acelex in Russia next month at the earliest.

The Russian COX-2 inhibitor market, to which Acelex belongs, is showing an annual growth rate of more than 30%. It is possible to expand the